Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality

The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality.

ISCHEMIA: La anatomía y no la función es la que marca el pronóstico

Now, this new analysis suggests that anatomic severity can predict events. However (surprisingly, once more), altering this severity through angioplasty does not change the prognosis for hard points such as death or infarction (referring to 4 years of follow-up).

Perhaps only the subgroup with greater anatomical severity somewhat benefits from angioplasty in terms of a reduction in death and infarction rates.

A total of 5179 patients with moderate to severe ischemia were randomized to an initial invasive strategy vs. a conservative strategy. An independent, blinded laboratory interpreted the extent and severity of coronary artery disease on computerized tomography (CT).

When comparing patients with no ischemia or mild ischemia vs. those with moderate or severe ischemia, no mortality increase was observed among the latter (moderate ischemia hazard ratio [HR]: 0.89; 95% confidence interval [CI]: 0.61 to 1.30; severe ischemia HR: 0.83; 95% CI: 0.57 to 1.21; p = 0.33).

The rate of non-fatal infarction increased with ischemia severity, although this is only a trend that becomes non-significant when adjusting for all variables.


Read also: Device Evolution Also Impacts on Valve in Valve.


This is very different from what was observed with the burden of coronary disease, given that, when comparing the extremes (no disease or mild disease vs. moderate or severe disease) there was almost a 3-fold increase in mortality (HR: 2.72; 95% CI: 1.06 to 6.98), and an almost 4-fold increase in infarction (HR: 3.78; 95% CI: 1.63 to 8.78).

The ischemic burden was not an indicator to select patients who might benefit from revascularization. In contrast, those with more severe anatomic disease (n = 659) who underwent revascularization showed a decrease in cardiovascular death and infarction at 4 years of follow-up (a difference of 6.3%; CI 95%: 0.2% to 12.4%). The difference only affected cardiovascular death, since all-cause death rates were similar.

Conclusion

Ischemia severity was not associated with increased risk, in contrast to what occurred with anatomy, where greater disease severity did translate into increased risk.

The initial invasive strategy did not decrease events across the spectrum of ischemic burden severity after 4 years of follow-up.

CIRCULATIONAHA-120-049755

Original Title: Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.

Reference: Harmony R. Reynolds et al. Circulation. 2021 Sep 28;144(13):1024-1038. doi: 10.1161/CIRCULATIONAHA.120.049755+.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...